Skip to content
OpenCapital
Get started

Corvus Pharmaceuticals CRVS Equity in earnings (losses) of equity method investees

Equity in earnings (losses) of equity method investees at other companies

Nektar Therapeutics logo
Nektar TherapeuticsNKTR
——

Other financials

Income statement

See full
Operating income-$14.9M-49.9%
Net income-$13.7M-190%
EPS (diluted)-$0.15-15.4%

Balance sheet

See full
Cash & equivalents$40.1M+702%
Total debt$834.0K-27.7%
Total equity$240.7M+388%
Total assets$253.2M+326%

Cash flow

See full
Operating cash flow-$10.4M-25.5%
CapEx$91.0K+153%
Free cash flow-$10.5M-26.1%

Valuation

See full
Market cap$1.1B+259%
Enterprise value$1.06B+251%

Returns & leverage

See full
Return on equity-30.5%-12.5pp
Debt / equity0×0.0×
Current ratio19.8×+14.9×

Where this comes from

Reported directly by Corvus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.

The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Corvus Pharmaceuticals's equity in earnings (losses) of equity method investees.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Corvus Pharmaceuticals's equity in earnings (losses) of equity method investees?
Corvus Pharmaceuticals (CRVS) reported equity in earnings (losses) of equity method investees of -$599K in Q1 2026.
How has Corvus Pharmaceuticals's equity in earnings (losses) of equity method investees changed year-over-year?
Corvus Pharmaceuticals's equity in earnings (losses) of equity method investees decreased by 11.1% year-over-year, from -$539K to -$599K.
What is the long-term trend for Corvus Pharmaceuticals's equity in earnings (losses) of equity method investees?
Over 3 years (2022 to 2025), Corvus Pharmaceuticals's equity in earnings (losses) of equity method investees has grown at a -41.9% compound annual growth rate (CAGR), from -$10.01M to -$1.96M.